Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Dalteparin
- Accession Number
- DB06779
- Type
- Small Molecule
- Groups
- Approved
- Description
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
- Synonyms
- alpha-heparin
- Product Ingredients
Ingredient UNII CAS InChI Key Dalteparin sodium 12M44VTJ7B Not Available Not applicable - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Fragmin Solution 25000 unit Intravenous; Subcutaneous Pfizer 1997-11-27 Not applicable Canada 
Fragmin Injection 10000 [iU]/.4mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US 
Fragmin Injection 15000 [iU]/.6mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Injection 2500 [iU]/.2mL Subcutaneous Pfizer Laboratories Div Pfizer Inc. 2015-04-01 Not applicable US Fragmin Injection 5000 [iU]/.2mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Solution 18000 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Injection 18000 [iU]/.72mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US Fragmin Solution 10000 unit Intravenous; Subcutaneous Pfizer 1995-12-31 Not applicable Canada Fragmin Solution 10000 unit Intravenous; Subcutaneous Pfizer 2011-02-01 Not applicable Canada Fragmin Injection 10000 [iU]/mL Subcutaneous Eisai Limited 1994-12-22 2017-02-10 US - International/Other Brands
- Boxol (Pharmacia) / Eurodal (Gland) / Ligoframin (Pfizer) / Low Liquemine (Roche)
- Categories
- UNII
- S79O08V79F
- CAS number
- 9005-49-6
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications.
Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).
It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
- Associated Conditions
- Pharmacodynamics
Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
- Mechanism of action
Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage.
Target Actions Organism AAntithrombin-III potentiatorHuman AVascular endothelial growth factor A inhibitorHuman ATissue factor pathway inhibitor inhibitorHuman UP-selectin inhibitorHuman - Absorption
Almost completely absorbed after subcutaneous (sc) doses, with a bioavialability of about 87%.
- Volume of distribution
3 litres
- Protein binding
Less than unfractionated heparin, which is more than 90%.
- Metabolism
Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.
- Route of elimination
After 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).
- Half life
Terminal Half life: Intravenous - 2 hours. Subcutaneous - 3-5hours
- Clearance
Excreted via kidneys. The plasma clearance rate is 33 mL/min.
- Toxicity
Overdosage: hemorrhagic complications. Adverse Drug Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. (uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the anticoagulant activities of Dalteparin. Investigational Abciximab Abciximab may increase the anticoagulant activities of Dalteparin. Approved Aceclofenac Aceclofenac may increase the anticoagulant activities of Dalteparin. Approved, Investigational Acemetacin The risk or severity of bleeding can be increased when Dalteparin is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Acenocoumarol may increase the anticoagulant activities of Dalteparin. Approved, Investigational Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Adapalene Adapalene may increase the anticoagulant activities of Dalteparin. Approved Alclofenac Alclofenac may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Aliskiren Dalteparin may increase the hyperkalemic activities of Aliskiren. Approved, Investigational Allylestrenol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Allylestrenol. Approved Alminoprofen Alminoprofen may increase the anticoagulant activities of Dalteparin. Experimental Aloxiprin Aloxiprin may increase the anticoagulant activities of Dalteparin. Experimental Alprostadil Alprostadil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Alteplase Alteplase may increase the anticoagulant activities of Dalteparin. Approved Altrenogest The therapeutic efficacy of Dalteparin can be decreased when used in combination with Altrenogest. Vet Approved Amikacin The therapeutic efficacy of Amikacin can be decreased when used in combination with Dalteparin. Approved, Investigational, Vet Approved Amiloride Dalteparin may increase the hyperkalemic activities of Amiloride. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the anticoagulant activities of Dalteparin. Approved Anagrelide Anagrelide may increase the anticoagulant activities of Dalteparin. Approved Ancrod Ancrod may increase the anticoagulant activities of Dalteparin. Approved, Investigational Andrographolide Andrographolide may increase the anticoagulant activities of Dalteparin. Investigational Anisodamine Anisodamine may increase the anticoagulant activities of Dalteparin. Investigational Anistreplase Anistreplase may increase the anticoagulant activities of Dalteparin. Approved Antipyrine Antipyrine may increase the anticoagulant activities of Dalteparin. Approved, Investigational Antithrombin III human Dalteparin may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Apixaban may increase the anticoagulant activities of Dalteparin. Approved Apocynin Apocynin may increase the anticoagulant activities of Dalteparin. Investigational Apremilast Apremilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Aprotinin The therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin. Approved, Investigational, Withdrawn Ardeparin Ardeparin may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Argatroban Argatroban may increase the anticoagulant activities of Dalteparin. Approved, Investigational Astaxanthin Astaxanthin may increase the anticoagulant activities of Dalteparin. Investigational Azapropazone Azapropazone may increase the anticoagulant activities of Dalteparin. Withdrawn Azelastine Azelastine may increase the anticoagulant activities of Dalteparin. Approved Azficel-T The risk or severity of adverse effects can be increased when Dalteparin is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil Dalteparin may increase the hyperkalemic activities of Azilsartan medoxomil. Approved, Investigational Balsalazide Balsalazide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Batroxobin Batroxobin may increase the anticoagulant activities of Dalteparin. Experimental Bazedoxifene Bazedoxifene may decrease the anticoagulant activities of Dalteparin. Approved, Investigational Becaplermin Becaplermin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Bemiparin Bemiparin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Bendazac Bendazac may increase the anticoagulant activities of Dalteparin. Experimental Benorilate Benorilate may increase the anticoagulant activities of Dalteparin. Experimental Benoxaprofen Benoxaprofen may increase the anticoagulant activities of Dalteparin. Withdrawn Benzydamine Benzydamine may increase the anticoagulant activities of Dalteparin. Approved Beraprost Beraprost may increase the anticoagulant activities of Dalteparin. Investigational Bevonium Bevonium may increase the anticoagulant activities of Dalteparin. Experimental Bivalirudin Bivalirudin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Brinase Brinase may increase the anticoagulant activities of Dalteparin. Experimental Bromfenac Bromfenac may increase the anticoagulant activities of Dalteparin. Approved Bucillamine Bucillamine may increase the anticoagulant activities of Dalteparin. Investigational Bufexamac Bufexamac may increase the anticoagulant activities of Dalteparin. Approved, Experimental Buflomedil Buflomedil may increase the anticoagulant activities of Dalteparin. Experimental Bumadizone Bumadizone may increase the anticoagulant activities of Dalteparin. Experimental Butylphthalide Butylphthalide may increase the anticoagulant activities of Dalteparin. Investigational Canagliflozin Dalteparin may increase the hyperkalemic activities of Canagliflozin. Approved Candesartan Dalteparin may increase the hyperkalemic activities of Candesartan. Experimental Candesartan cilexetil Dalteparin may increase the hyperkalemic activities of Candesartan cilexetil. Approved Cangrelor Cangrelor may increase the anticoagulant activities of Dalteparin. Approved Caplacizumab Caplacizumab may increase the anticoagulant activities of Dalteparin. Investigational Carbaspirin calcium Carbaspirin calcium may increase the anticoagulant activities of Dalteparin. Experimental, Investigational Carprofen Carprofen may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved, Withdrawn Carvedilol The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Carvedilol. Approved, Investigational Castanospermine Castanospermine may increase the anticoagulant activities of Dalteparin. Experimental Celecoxib Celecoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Certoparin Dalteparin may increase the anticoagulant activities of Certoparin. Approved, Investigational Chlormadinone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Chlormadinone. Experimental Chloroquine Chloroquine may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Dalteparin. Investigational, Withdrawn Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the anticoagulant activities of Dalteparin. Approved Cilostazol Cilostazol may increase the anticoagulant activities of Dalteparin. Approved, Investigational Clonixin Clonixin may increase the anticoagulant activities of Dalteparin. Approved Clopidogrel Clopidogrel may increase the anticoagulant activities of Dalteparin. Approved Cloricromen Cloricromen may increase the anticoagulant activities of Dalteparin. Experimental Clorindione Clorindione may increase the anticoagulant activities of Dalteparin. Experimental Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Dalteparin is combined with Collagenase clostridium histolyticum. Approved, Investigational Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Dalteparin. Approved Curcumin Curcumin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Cyclosporine The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Dalteparin. Approved Daidzein Daidzein may decrease the anticoagulant activities of Dalteparin. Experimental Danaparoid Danaparoid may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Darexaban Dalteparin may increase the anticoagulant activities of Darexaban. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Deferasirox The risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox. Approved, Investigational Defibrotide Defibrotide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Demegestone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Demegestone. Approved Deoxycholic Acid The risk or severity of adverse effects can be increased when Dalteparin is combined with Deoxycholic Acid. Approved Dersalazine Dersalazine may increase the anticoagulant activities of Dalteparin. Investigational Desirudin Dalteparin may increase the anticoagulant activities of Desirudin. Approved Desmoteplase Desmoteplase may increase the anticoagulant activities of Dalteparin. Investigational Desogestrel The therapeutic efficacy of Dalteparin can be decreased when used in combination with Desogestrel. Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Dalteparin. Approved, Investigational Dextran Dalteparin may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dalteparin. Approved, Vet Approved Dicoumarol Dicoumarol may increase the anticoagulant activities of Dalteparin. Approved Dienestrol Dienestrol may decrease the anticoagulant activities of Dalteparin. Approved, Investigational Dienogest The therapeutic efficacy of Dalteparin can be decreased when used in combination with Dienogest. Approved Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Dalteparin. Approved, Investigational Difenpiramide Difenpiramide may increase the anticoagulant activities of Dalteparin. Experimental Diflunisal Diflunisal may increase the anticoagulant activities of Dalteparin. Approved, Investigational Diphenadione Diphenadione may increase the anticoagulant activities of Dalteparin. Experimental Dipyridamole Dipyridamole may increase the anticoagulant activities of Dalteparin. Approved Ditazole Ditazole may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Drospirenone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Drospirenone. Approved Drotrecogin alfa Drotrecogin alfa may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Droxicam Droxicam may increase the anticoagulant activities of Dalteparin. Withdrawn Duvelisib Duvelisib may increase the anticoagulant activities of Dalteparin. Investigational Dydrogesterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Dydrogesterone. Approved, Investigational, Withdrawn E-6201 E-6201 may increase the anticoagulant activities of Dalteparin. Investigational Edetic Acid Edetic Acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Edoxaban Edoxaban may increase the anticoagulant activities of Dalteparin. Approved Enoxaparin Enoxaparin may increase the anticoagulant activities of Dalteparin. Approved Epimestrol Epimestrol may decrease the anticoagulant activities of Dalteparin. Experimental Epinastine Epinastine may increase the anticoagulant activities of Dalteparin. Approved, Investigational Epirizole Epirizole may increase the anticoagulant activities of Dalteparin. Approved Eplerenone Dalteparin may increase the hyperkalemic activities of Eplerenone. Approved Eplivanserin Eplivanserin may increase the anticoagulant activities of Dalteparin. Investigational Epoprostenol Epoprostenol may increase the anticoagulant activities of Dalteparin. Approved Eprosartan Dalteparin may increase the hyperkalemic activities of Eprosartan. Approved Eptifibatide Eptifibatide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Equol Equol may decrease the anticoagulant activities of Dalteparin. Investigational Estradiol Estradiol may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estriol Estriol may decrease the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Estrogens, esterified Estrogens, esterified may decrease the anticoagulant activities of Dalteparin. Approved Estrone Estrone may decrease the anticoagulant activities of Dalteparin. Approved Etanercept Etanercept may increase the anticoagulant activities of Dalteparin. Approved, Investigational Ethenzamide Ethenzamide may increase the anticoagulant activities of Dalteparin. Experimental Ethinyl Estradiol Ethinyl Estradiol may decrease the anticoagulant activities of Dalteparin. Approved Ethyl biscoumacetate Dalteparin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethynodiol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Ethynodiol. Experimental Etodolac Etodolac may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the anticoagulant activities of Dalteparin. Approved, Investigational Etonogestrel The therapeutic efficacy of Dalteparin can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoricoxib Etoricoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the anticoagulant activities of Dalteparin. Investigational, Nutraceutical Exisulind Exisulind may increase the anticoagulant activities of Dalteparin. Investigational Felbinac Felbinac may increase the anticoagulant activities of Dalteparin. Experimental Fenbufen Fenbufen may increase the anticoagulant activities of Dalteparin. Approved Fenoprofen Fenoprofen may increase the anticoagulant activities of Dalteparin. Approved Fentiazac Fentiazac may increase the anticoagulant activities of Dalteparin. Experimental Feprazone Feprazone may increase the anticoagulant activities of Dalteparin. Experimental Ferulic acid Ferulic acid may increase the anticoagulant activities of Dalteparin. Experimental Fibrinolysin Fibrinolysin may increase the anticoagulant activities of Dalteparin. Investigational Fimasartan Dalteparin may increase the hyperkalemic activities of Fimasartan. Approved, Investigational Floctafenine Floctafenine may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Fluindione Dalteparin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flunixin Flunixin may increase the anticoagulant activities of Dalteparin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the anticoagulant activities of Dalteparin. Experimental Fluoxetine Fluoxetine may increase the antiplatelet activities of Dalteparin. Approved, Vet Approved Flurbiprofen Flurbiprofen may increase the anticoagulant activities of Dalteparin. Approved, Investigational Fluvoxamine Fluvoxamine may increase the antiplatelet activities of Dalteparin. Approved, Investigational Fondaparinux Fondaparinux sodium may increase the anticoagulant activities of Dalteparin. Approved, Investigational Forasartan Dalteparin may increase the hyperkalemic activities of Forasartan. Experimental Fosinopril The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Fosinopril. Approved Gabexate Dalteparin may increase the anticoagulant activities of Gabexate. Investigational Genistein Genistein may decrease the anticoagulant activities of Dalteparin. Investigational Gestodene The therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestodene. Approved, Investigational Gestonorone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestonorone. Experimental Gestrinone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestrinone. Approved Guacetisal Guacetisal may increase the anticoagulant activities of Dalteparin. Experimental Hemin Hemin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the anticoagulant activities of Dalteparin. Experimental Heparin Heparin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Hexestrol Hexestrol may decrease the anticoagulant activities of Dalteparin. Withdrawn Higenamine Higenamine may increase the anticoagulant activities of Dalteparin. Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Hydroxyprogesterone caproate. Approved, Investigational Hydroxytyrosol Hydroxytyrosol may increase the anticoagulant activities of Dalteparin. Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin. Approved Ibudilast Ibudilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Ibuprofen The risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dalteparin. Approved Ibuproxam Ibuproxam may increase the anticoagulant activities of Dalteparin. Withdrawn Icatibant Icatibant may increase the anticoagulant activities of Dalteparin. Approved, Investigational Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Nutraceutical Idraparinux Idraparinux may increase the anticoagulant activities of Dalteparin. Investigational Ifenprodil Ifenprodil may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Ifetroban Ifetroban may increase the anticoagulant activities of Dalteparin. Investigational Iloprost Iloprost may increase the anticoagulant activities of Dalteparin. Approved, Investigational Imidazole salicylate Imidazole salicylate may increase the anticoagulant activities of Dalteparin. Experimental Indobufen Indobufen may increase the anticoagulant activities of Dalteparin. Investigational Indomethacin Indomethacin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Indoprofen Indoprofen may increase the anticoagulant activities of Dalteparin. Withdrawn Irbesartan Dalteparin may increase the hyperkalemic activities of Irbesartan. Approved, Investigational Isoxicam Isoxicam may increase the anticoagulant activities of Dalteparin. Withdrawn Kebuzone Kebuzone may increase the anticoagulant activities of Dalteparin. Experimental Ketanserin Ketanserin may increase the anticoagulant activities of Dalteparin. Investigational Ketoprofen Ketoprofen may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dalteparin. Approved Labetalol The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Labetalol. Approved Leflunomide Leflunomide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Lepirudin Dalteparin may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Dalteparin may increase the anticoagulant activities of Letaxaban. Investigational Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Dalteparin. Approved, Investigational Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Dalteparin. Approved, Investigational Linsidomine Linsidomine may increase the anticoagulant activities of Dalteparin. Experimental Lisofylline Lisofylline may increase the anticoagulant activities of Dalteparin. Investigational Lonazolac Lonazolac may increase the anticoagulant activities of Dalteparin. Experimental Lornoxicam Lornoxicam may increase the anticoagulant activities of Dalteparin. Approved, Investigational Losartan The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Losartan. Approved Loxoprofen Loxoprofen may increase the anticoagulant activities of Dalteparin. Approved, Investigational Lumiracoxib Lumiracoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational Lynestrenol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Lynestrenol. Approved, Investigational Magnesium salicylate Magnesium salicylate may increase the anticoagulant activities of Dalteparin. Approved Masoprocol Masoprocol may increase the anticoagulant activities of Dalteparin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Medrogestone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Mefenamic acid Mefenamic acid may increase the anticoagulant activities of Dalteparin. Approved Megestrol acetate The therapeutic efficacy of Dalteparin can be decreased when used in combination with Megestrol acetate. Approved, Investigational, Vet Approved Melagatran Dalteparin may increase the anticoagulant activities of Melagatran. Experimental Meloxicam Meloxicam may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Mesalazine Mesalazine may increase the anticoagulant activities of Dalteparin. Approved Mestranol Mestranol may decrease the anticoagulant activities of Dalteparin. Approved Metamizole Metamizole may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Methallenestril Methallenestril may decrease the anticoagulant activities of Dalteparin. Experimental Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Dalteparin. Approved, Vet Approved Methylestrenolone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Methylestrenolone. Experimental Metoprolol The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Metoprolol. Approved, Investigational Milrinone Milrinone may increase the anticoagulant activities of Dalteparin. Approved Mizoribine Mizoribine may increase the anticoagulant activities of Dalteparin. Investigational Mofebutazone Mofebutazone may increase the anticoagulant activities of Dalteparin. Experimental Moxestrol Moxestrol may decrease the anticoagulant activities of Dalteparin. Experimental Mycophenolate mofetil Mycophenolate mofetil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the anticoagulant activities of Dalteparin. Approved Nabumetone Nabumetone may increase the anticoagulant activities of Dalteparin. Approved Nadroparin Dalteparin may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Nafamostat may increase the anticoagulant activities of Dalteparin. Approved, Investigational Naftifine Naftifine may increase the anticoagulant activities of Dalteparin. Approved Naftopidil Naftopidil may increase the anticoagulant activities of Dalteparin. Investigational Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dalteparin. Approved, Vet Approved Neomycin The therapeutic efficacy of Neomycin can be decreased when used in combination with Dalteparin. Approved, Vet Approved Nepafenac Nepafenac may increase the anticoagulant activities of Dalteparin. Approved, Investigational Nifenazone Nifenazone may increase the anticoagulant activities of Dalteparin. Experimental Niflumic Acid Niflumic Acid may increase the anticoagulant activities of Dalteparin. Approved Nimesulide Nimesulide may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Nintedanib The risk or severity of adverse effects can be increased when Dalteparin is combined with Nintedanib. Approved Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Dalteparin. Investigational Nomegestrol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Nomegestrol. Approved Norethisterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Norethisterone. Approved Norgestrienone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Norgestrienone. Experimental Obinutuzumab The risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab. Approved, Investigational Olmesartan Dalteparin may increase the hyperkalemic activities of Olmesartan. Approved, Investigational Olopatadine Olopatadine may increase the anticoagulant activities of Dalteparin. Approved Olsalazine Olsalazine may increase the anticoagulant activities of Dalteparin. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Dalteparin is combined with Omacetaxine mepesuccinate. Approved, Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical Omega-3-carboxylic acids The therapeutic efficacy of Dalteparin can be increased when used in combination with Omega-3-carboxylic acids. Approved, Investigational Orgotein Orgotein may increase the anticoagulant activities of Dalteparin. Vet Approved Otamixaban Otamixaban may increase the anticoagulant activities of Dalteparin. Investigational Oxaprozin Oxaprozin may increase the anticoagulant activities of Dalteparin. Approved Oxyphenbutazone Oxyphenbutazone may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Ozagrel Ozagrel may increase the anticoagulant activities of Dalteparin. Investigational Palifermin The serum concentration of Palifermin can be increased when it is combined with Dalteparin. Approved Palmidrol Palmidrol may increase the anticoagulant activities of Dalteparin. Experimental, Nutraceutical Parecoxib Parecoxib may increase the anticoagulant activities of Dalteparin. Approved Parnaparin Parnaparin may increase the anticoagulant activities of Dalteparin. Approved, Investigational Paromomycin The therapeutic efficacy of Paromomycin can be decreased when used in combination with Dalteparin. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Dalteparin. Approved, Investigational Parthenolide Parthenolide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Pentaerythritol Tetranitrate Pentaerythritol Tetranitrate may increase the anticoagulant activities of Dalteparin. Approved Pentosan Polysulfate Pentosan Polysulfate may increase the anticoagulant activities of Dalteparin. Approved Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Dalteparin. Approved, Investigational Phenindione Phenindione may increase the anticoagulant activities of Dalteparin. Approved, Investigational Phenprocoumon Phenprocoumon may increase the anticoagulant activities of Dalteparin. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the anticoagulant activities of Dalteparin. Approved Phenylbutazone Phenylbutazone may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Picotamide Picotamide may increase the anticoagulant activities of Dalteparin. Experimental Pimecrolimus Pimecrolimus may increase the anticoagulant activities of Dalteparin. Approved, Investigational Pirfenidone Pirfenidone may increase the anticoagulant activities of Dalteparin. Approved, Investigational Piroxicam Piroxicam may increase the anticoagulant activities of Dalteparin. Approved, Investigational Pirprofen Pirprofen may increase the anticoagulant activities of Dalteparin. Experimental Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Dalteparin. Approved Potassium Chloride The risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Dalteparin. Approved, Withdrawn Potassium Citrate Dalteparin may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Pranoprofen Pranoprofen may increase the anticoagulant activities of Dalteparin. Experimental, Investigational Prasugrel Prasugrel may increase the anticoagulant activities of Dalteparin. Approved Progesterone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone. Approved, Vet Approved Proglumetacin Proglumetacin may increase the anticoagulant activities of Dalteparin. Experimental Promegestone The therapeutic efficacy of Dalteparin can be decreased when used in combination with Promegestone. Experimental Promestriene Promestriene may decrease the anticoagulant activities of Dalteparin. Investigational Propacetamol Propacetamol may increase the anticoagulant activities of Dalteparin. Approved, Investigational Propafenone The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Propafenone. Approved Propranolol The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Propranolol. Approved, Investigational Propyphenazone Propyphenazone may increase the anticoagulant activities of Dalteparin. Experimental Proquazone Proquazone may increase the anticoagulant activities of Dalteparin. Experimental Protein C Dalteparin may increase the anticoagulant activities of Protein C. Approved Protein S human Dalteparin may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Dalteparin may increase the anticoagulant activities of Protocatechualdehyde. Approved PTC299 PTC299 may increase the anticoagulant activities of Dalteparin. Investigational Quinestrol Quinestrol may decrease the anticoagulant activities of Dalteparin. Approved Quingestanol The therapeutic efficacy of Dalteparin can be decreased when used in combination with Quingestanol. Experimental Ramatroban Ramatroban may increase the anticoagulant activities of Dalteparin. Investigational Relcovaptan Relcovaptan may increase the anticoagulant activities of Dalteparin. Investigational Resveratrol Resveratrol may increase the anticoagulant activities of Dalteparin. Approved, Experimental, Investigational Reteplase Reteplase may increase the anticoagulant activities of Dalteparin. Approved, Investigational Reviparin Dalteparin may increase the anticoagulant activities of Reviparin. Approved, Investigational Ridogrel Ridogrel may increase the anticoagulant activities of Dalteparin. Approved Rivaroxaban Dalteparin may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Sacubitril Dalteparin may increase the hyperkalemic activities of Sacubitril. Approved Salicylamide Salicylamide may increase the anticoagulant activities of Dalteparin. Approved Salicylic acid The risk or severity of bleeding can be increased when Salicylic acid is combined with Dalteparin. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the anticoagulant activities of Dalteparin. Approved Saprisartan Dalteparin may increase the hyperkalemic activities of Saprisartan. Experimental Saralasin Dalteparin may increase the hyperkalemic activities of Saralasin. Investigational Sarpogrelate Sarpogrelate may increase the anticoagulant activities of Dalteparin. Investigational Saruplase Saruplase may increase the anticoagulant activities of Dalteparin. Experimental Secoisolariciresinol Secoisolariciresinol may decrease the anticoagulant activities of Dalteparin. Investigational Selexipag Selexipag may increase the anticoagulant activities of Dalteparin. Approved Semapimod Semapimod may increase the anticoagulant activities of Dalteparin. Investigational Seratrodast Seratrodast may increase the anticoagulant activities of Dalteparin. Approved Serrapeptase Serrapeptase may increase the anticoagulant activities of Dalteparin. Investigational Sevoflurane Sevoflurane may increase the anticoagulant activities of Dalteparin. Approved, Vet Approved Sodium Citrate The risk or severity of bleeding can be increased when Dalteparin is combined with Sodium Citrate. Approved, Investigational Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dalteparin. Approved SRT501 SRT501 may increase the anticoagulant activities of Dalteparin. Investigational Streptokinase Streptokinase may increase the anticoagulant activities of Dalteparin. Approved, Investigational Sugammadex Sugammadex may increase the anticoagulant activities of Dalteparin. Approved Sulfasalazine The risk or severity of bleeding can be increased when Sulfasalazine is combined with Dalteparin. Approved Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dalteparin. Approved, Investigational Sulodexide Sulodexide may increase the anticoagulant activities of Dalteparin. Approved, Investigational Suprofen Suprofen may increase the anticoagulant activities of Dalteparin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the anticoagulant activities of Dalteparin. Experimental Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dalteparin. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin. Approved Tarenflurbil Tarenflurbil may increase the anticoagulant activities of Dalteparin. Investigational Tasosartan Dalteparin may increase the hyperkalemic activities of Tasosartan. Approved Telmisartan Dalteparin may increase the hyperkalemic activities of Telmisartan. Approved, Investigational Tenecteplase Tenecteplase may increase the anticoagulant activities of Dalteparin. Approved Tenidap Tenidap may increase the anticoagulant activities of Dalteparin. Experimental Tenoxicam Tenoxicam may increase the anticoagulant activities of Dalteparin. Approved Tepoxalin Tepoxalin may increase the anticoagulant activities of Dalteparin. Vet Approved Teriflunomide Teriflunomide may increase the anticoagulant activities of Dalteparin. Approved Tesmilifene Tesmilifene may increase the anticoagulant activities of Dalteparin. Investigational Testosterone cypionate The therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone cypionate. Approved Testosterone enanthate The therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone enanthate. Approved Testosterone undecanoate The therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone undecanoate. Approved, Investigational Tiaprofenic acid Tiaprofenic acid may increase the anticoagulant activities of Dalteparin. Approved Tibolone Tibolone may increase the anticoagulant activities of Dalteparin. Approved, Investigational Ticagrelor Ticagrelor may increase the anticoagulant activities of Dalteparin. Approved Ticlopidine Ticlopidine may increase the anticoagulant activities of Dalteparin. Approved Tinoridine Tinoridine may increase the anticoagulant activities of Dalteparin. Investigational Tinzaparin Tinzaparin may increase the anticoagulant activities of Dalteparin. Approved Tioclomarol Tioclomarol may increase the anticoagulant activities of Dalteparin. Experimental Tipranavir Tipranavir may increase the anticoagulant activities of Dalteparin. Approved, Investigational Tirofiban Tirofiban may increase the anticoagulant activities of Dalteparin. Approved Tolfenamic Acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dalteparin. Approved, Investigational Tolmetin Tolmetin may increase the anticoagulant activities of Dalteparin. Approved Tositumomab The risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab. Approved, Investigational Tranilast Tranilast may increase the anticoagulant activities of Dalteparin. Approved, Investigational Trapidil Trapidil may increase the anticoagulant activities of Dalteparin. Approved Treprostinil Treprostinil may increase the anticoagulant activities of Dalteparin. Approved, Investigational Triamterene Dalteparin may increase the hyperkalemic activities of Triamterene. Approved Tribenoside Tribenoside may increase the anticoagulant activities of Dalteparin. Experimental Triflusal Triflusal may increase the anticoagulant activities of Dalteparin. Approved, Investigational Triptolide Triptolide may increase the anticoagulant activities of Dalteparin. Investigational Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dalteparin. Approved Troxerutin Dalteparin may increase the anticoagulant activities of Troxerutin. Investigational Urokinase Urokinase may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Valdecoxib Valdecoxib may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Valsartan Dalteparin may increase the hyperkalemic activities of Valsartan. Approved, Investigational Venlafaxine Venlafaxine may increase the antiplatelet activities of Dalteparin. Approved Vitamin E Vitamin E may increase the anticoagulant activities of Dalteparin. Approved, Nutraceutical, Vet Approved Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Dalteparin. Approved Warfarin Warfarin may increase the anticoagulant activities of Dalteparin. Approved Ximelagatran Ximelagatran may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the anticoagulant activities of Dalteparin. Approved, Investigational Zeranol Zeranol may decrease the anticoagulant activities of Dalteparin. Vet Approved Zileuton Zileuton may increase the anticoagulant activities of Dalteparin. Approved, Investigational, Withdrawn Zomepirac Zomepirac may increase the anticoagulant activities of Dalteparin. Withdrawn - Food Interactions
- Herbs (anticoagulant/antiplatelet properties such as ginseng, ginkgo, ginger, garlic)
References
- General References
- King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr;100(4):535-40. [PubMed:6367579]
- Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980 Oct 16;303(16):902-7. [PubMed:6997743]
- Ockelford PA, Patterson J, Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046-9. [PubMed:2559484]
- Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577-84. [PubMed:2158151]
- Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A: Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol. 1989;37(4):415-8. [PubMed:2557219]
- Holmer E, Soderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16 Suppl 2:1-7. [PubMed:3744129]
- Malm K, Dahlback B, Arnljots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003 Apr 15;111(5):1659-66. [PubMed:12655212]
- Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006 Jul;91(7):976-9. Epub 2006 Jun 1. [PubMed:16757417]
- Schmid P, Brodmann D, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19. [PubMed:19175499]
- Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N: Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286-94. Epub 2006 Oct 25. [PubMed:17166617]
- Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
- Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. [PubMed:11011804]
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]
- External Links
- KEGG Drug
- D03353
- PubChem Substance
- 347910371
- Wikipedia
- Dalteparin_sodium
- ATC Codes
- B01AB04 — Dalteparin
- AHFS Codes
- 20:12.04.16 — Heparins
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection Subcutaneous 10000 [iU]/.4mL Injection Subcutaneous 10000 [iU]/mL Injection Subcutaneous 12500 [iU]/.5mL Injection Subcutaneous 15000 [iU]/.6mL Injection Subcutaneous 18000 [iU]/.72mL Injection Subcutaneous 2500 [iU]/.2mL Injection Subcutaneous 25000 [iU]/mL Injection Subcutaneous 5000 [iU]/.2mL Injection Subcutaneous 7500 [iU]/.3mL Solution Intravenous; Subcutaneous 10000 unit Solution Intravenous; Subcutaneous 12500 unit Solution Intravenous; Subcutaneous 15000 unit Solution Intravenous; Subcutaneous 18000 unit Solution Intravenous; Subcutaneous 2500 unit Solution Intravenous; Subcutaneous 25000 unit Solution Intravenous; Subcutaneous 3500 unit Solution Intravenous; Subcutaneous 5000 unit Solution Intravenous; Subcutaneous 7500 unit Liquid Intravenous; Subcutaneous 2500 unit - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
- Gene Name
- SERPINC1
- Uniprot ID
- P01008
- Uniprot Name
- Antithrombin-III
- Molecular Weight
- 52601.935 Da
References
- Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Vascular endothelial growth factor receptor binding
- Specific Function
- Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
- Gene Name
- VEGFA
- Uniprot ID
- P15692
- Uniprot Name
- Vascular endothelial growth factor A
- Molecular Weight
- 27042.205 Da
References
- Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010 Oct 12. [PubMed:21091776]
- Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10. [PubMed:17692905]
- Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action...
- Gene Name
- TFPI
- Uniprot ID
- P10646
- Uniprot Name
- Tissue factor pathway inhibitor
- Molecular Weight
- 35014.835 Da
References
- Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev. 2004 Summer;22(2):121-34. [PubMed:15179449]
- Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M: Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. Epub 2010 Aug 3. [PubMed:20682597]
- Bendz B, Andersen TO, Sandset PM: Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. [PubMed:10847421]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sialic acid binding
- Specific Function
- Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligan...
- Gene Name
- SELP
- Uniprot ID
- P16109
- Uniprot Name
- P-selectin
- Molecular Weight
- 90833.105 Da
References
- Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Syndecan binding
- Specific Function
- Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Se...
- Gene Name
- HPSE
- Uniprot ID
- Q9Y251
- Uniprot Name
- Heparanase
- Molecular Weight
- 61148.17 Da
References
- Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]
Drug created on September 14, 2010 10:21 / Updated on August 15, 2018 09:54